Growth through expansion Vetio is expanding manufacturing capacity and headcount, including a new 35,000 sq ft facility and Florida expansion. Sales opportunities exist in scalable CDMO partnerships, outsourcing additional product lines, and cross-selling development, regulatory, and analytical services to cover full lifecycle needs.

Acquisition impact Swedencare AB acquired Vetio in 2021, positioning the company for continued growth with maintained safety, quality, and compliance. Potential upsell to Swedencare’s extended network and portfolio, plus leverage parent company resources for global market access and co-development deals.

Full-service CDMO Vetio combines development, technical services, manufacturing, and analytical services under a Quality by Design framework. This positions Vetio as a single-source partner for animal health products, offering opportunities to upsell integrated services to clientes seeking end-to-end solutions.

Mid-market focus With revenue in the $50–$100 million range and a relatively mid-sized employee base, Vetio targets mid-market animal health brands looking for scalable, compliant manufacturing and development support. There is room to win mid-sized biotech and veterinary pharma accounts seeking reliable CDMO partners.

Quality and compliance A strong emphasis on safety, quality, and regulatory compliance together with a Design of Experiments approach signals readiness for complex or highly regulated products. Opportunities exist to pursue contracts requiring formal quality systems alignment, audits, and accelerated approval pathways for new formulations or regional launches.